Martin Shkreli

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) announced Thursday the release of a 99-cent alternative to Allergan PLC Ordinary Shares (NYSE: AGN)'s Restasis to address the 30 million Americans suffering from Dry Eye Disease. According to Imprimis, Restasis lacks generic competition despite a...

"Pharma bro" Martin Shkreli has some harsh words for Merck & Co., Inc. (NYSE: MRK)'s CEO Ken Frazier after the executive distanced himself from President Donald Trump. Frazier is one of four executives who stepped down from the president's American Manufacturing Council after Trump's initial...

After years of investigation and a six-week trial, "Pharma Bro" Martin Shkreli was found guilty on two counts of securities fraud and one count of conspiracy to commit securities fraud. The jury found him not guilty on five other charges after five days of deliberation. "We're...

After years of case-building, federal prosecutors will finally meet Martin Shkreli in court Monday, June 26, for a six-week trial. The former hedge-fund manager and pharmaceutical executive will face eight charges of securities and wire fraud, for which he has pleaded not guilty. “I’m...

Even under proverbial shackles, Martin Shkreli continues to flex his powerful muscles. The founder and former CEO of Turing Pharmaceuticals could reclaim corporate leadership ahead of the June 26 start to his securities fraud trial. The board of Turing met Wednesday and shareholders voted to elect...

Let’s talk Daraprim — again. The controversially pricey drug that set regulators on their toes and prompted critical evaluations of pharmaceutical practices nearly switched hands this week as Turing Pharmaceuticals considered a $100 million cash offer, according to Endpoints News....

A day after Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) announced plans to develop a lower-priced alternative to Mallinckrodt PLC (NYSE: MNK)’s HP Acthar Gel, Martin Shkreli told Benzinga the proliferating market shorts against Mallinckrodt are “much ado about nothing.” “...

Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) wants to stop egregious drug pricing issues, and Mallinckrodt PLC (NYSE: MNK) is its next target. Imprimis announced it will pursue a lower priced alternative to Mallinckrodt's HP Acthar Gel, which grossed sales of $1.3 billion in the prior year....

Academy Award-winning actor Matthew McConaughey stars in the new movie “Gold,” which tells the story of fraudulent Canadian gold mining company Bre-X. Bre-X is only one of hundreds of crazy Wall Street characters and stories fit for the big screen. Here are four crazy Wall Street...

Zosano Pharma Corp (NASDAQ: ZSAN) opened 78 percent higher Monday on news that it met both co-primary endpoints in the ZOTRIP pivotal efficacy migraine trial. However, the effect was swiftly mitigated by Martin Shkreli’s Facebook Inc (NASDAQ: FB) post contradicting investor instinct....

Immunomedics, Inc. (NASDAQ: IMMU) shares are on a strong upswing, hitting a two-year high, on roughly 27-times their average volume. The Catalyst The biopharmaceutical company specializing in antibody-based therapeutics announced that it has inked an exclusive global licensing agreement with...

Investors may not have been thrilled with Gilead Sciences, Inc. (NASDAQ: GILD)’s fourth-quarter report, but Martin Shkreli was ecstatic. Following the Tuesday release, which drove Gilead shares to their lowest point since 2014, the pharmaceutical giant advised investors to buy shares...

Mallinckrodt PLC (NYSE: MNK), a developer of branded and generic specialty pharmaceutical products and therapies, is a popular stock among short sellers. Back in January, Martin Shkreli explained to Benzinga why a Federal Trade Commission lawsuit against the company is justified. Prior to that,...

Shares of Galena Biopharma Inc (NASDAQ: GALE) are up nearly 50 percent Monday after the company announced the results from a Data Safety Monitoring Board (DSMB) meeting related to two investigator-sponsored (IST) combination clinical trials of NeuVax with trastuzumab. According to the press...

Following a report exposing Martin Shkreli as a whistleblower against Mallinckrodt PLC (NYSE: MNK), Shkreli told Benzinga that the Federal Trade Commission's new lawsuit is just. “Questcor [Mallinckrodt subsidiary] stopped me from competing with their very high-priced drug which made...